Skip to main
  1. Stocks
  2. Aardvark Therapeutics Inc
  3. Forecast
AARD

AARD Stock Forecast & Price Target

AARD Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 13%
Hold 38%
Sell 13%
Strong Sell 0%

Bulls say

Aardvark Therapeutics is supported by exploratory data that suggest ARD-101 produces a real pharmacologic effect in Prader-Willi syndrome, with a modest HQ-CT reduction versus placebo by week two and a 6-point average reduction in the open-label extension among participants switching from placebo. The fact that scores returned near baseline after discontinuation, while placebo showed less rebound, strengthens the interpretation that the observed changes were drug-related rather than random variation, even though the HERO trial was terminated early after randomizing 67 of 90 planned participants. Its favorable tolerability profile, with most adverse events mild to moderate, further supports the case that a gut-restricted oral TAS2R agonist could advance as a differentiated metabolic therapy.

Bears say

Aardvark Therapeutics is a clinical-stage company with no approved products, so its valuation depends heavily on ARD-101 advancing through a still-uncertain regulatory path after the FDA clinical hold and the termination of the HERO and OLE trials. Although the hold was lifted and no cardiac events were seen in the recent ECG study at 200mg and 400mg BID, the company still faces unresolved questions around Phase 3 design, safety interpretation, and whether the initial efficacy signals in PWS are strong enough to support meaningful commercialization. The outlook is further weakened by financing overhang and the risk that ARD-101 may not achieve the market penetration previously hoped for across PWS, hypothalamic obesity, and obesity.

AARD has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 38% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aardvark Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

AARD Analyst Forecast & Price Prediction

Get the latest AARD stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AARD

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aardvark Therapeutics Inc (AARD) Forecast

Analysts have given AARD a Buy based on their latest research and market trends.

According to 8 analysts, AARD has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aardvark Therapeutics Inc (AARD)


AARD Analyst Forecast & Price Prediction

Get the latest AARD stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AARD

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover AARD stock data and trends